The cancer news you missed at ESMO
While you were doing your weekend, cancer researchers were in Barcelona for this year’s meeting of the European Society of Medical Oncology. They were also making some news.
New data released by Amgen showed that its experimental KRAS-blocking drug had minimal tumor-shrinking effects in patients with advanced colorectal cancer. The disappointing results will likely raise new questions over whether the drug can be broadly effective against different types of solid tumors.
Other data released at the conference showed two competing PARP inhibitors, one from Astrazeneca and Merck, the other from GlaxoSmithKline, reduced the risk of ovarian cancer from returning following surgery.
New data released by Amgen showed that its experimental KRAS-blocking drug had minimal tumor-shrinking effects in patients with advanced colorectal cancer. The disappointing results will likely raise new questions over whether the drug can be broadly effective against different types of solid tumors.
Other data released at the conference showed two competing PARP inhibitors, one from Astrazeneca and Merck, the other from GlaxoSmithKline, reduced the risk of ovarian cancer from returning following surgery.
No hay comentarios:
Publicar un comentario